



Date: 13th October, 2022

ONLINE FILING

The Secretary The Secretary, National Stock Exchange of India Ltd. BSE Ltd.

Exchange Plaza, Bandra-Kurla Phiroze Jeejeebhoy Towers, Complex, Bandra (E), Dalal Street,

Mumbai-400 051 Mumbai-400 001

NSE Symbol: ARTEMISMED Scrip Code: 542919

Dear Sir/Ma'am,

Sub: Submission of Reconciliation of Share Capital Audit Report

Please find enclosed herewith Reconciliation of Share Capital Audit Report under Regulation 76 of SEBI (Depositories & Participants) Regulations, 2018 issued by M/s DMK Associates, Practicing Company Secretaries for the quarter and half year ended 30th September, 2022.

Submitted for your information & records.

Thanking you,

Yours Faithfully,

For Artemis Medicare Services Limited

Dr. Devlina Chakravarty **Managing Director** DIN: 07107875







To,
The Board of Directors
Artemis Medicare Services Limited
Plot No. 14 Sector 20,
Dwarka,
New Delhi-110075

Sub: Report on Reconciliation of Share Capital Audit of the Company for the quarter ended September 30, 2022.

We have examined the soft copy of Register of Members, beneficiary details furnished by the Depositories and other records maintained by M/s. Artemis Medicare Services limited-CIN No. L85110DL2004PLC126414 (hereinafter referred to as 'the Company') and its Registrar and Share Transfer Agent for Electronic Connectivity, M/s. Alankit Assignments Limited, for giving report in accordance with the Circular No. D&CC/FITTC/CIR-16/2002 December 31, 2002 issued by the Securities and Exchange Board of India and Regulation 76 of SEBI (Depositories and Participants) Regulations, 2018 (as amended).

In our opinion and to the best of our knowledge and according to the information and explanations given to us and based on such verification as considered necessary, we hereby submit our report for the quarter ended **September 30, 2022** of the Company.

1.	For Quarter Ended	30.09.2022		
2.	ISIN	INE025R01021		
3.	Face Value	Re. 1/- per equity share		
4.	Name of the Company	Artemis Medicare Services Limited		
5.	Registered Office Address	Plot No. 14 Sector 20, Dwarka, South West Delhi -110075		
6.	Correspondence Address	Artemis Hospital, Sector-51, Gurugram-122001(Haryana)		
7.	Telephone & Fax. Nos.	Tel: 91-124-4807-180		
8.	Email Address	investor@artemishospitals.co	<u>om</u>	
9.	Names of the Stock Exchanges where the company's securities are listed	National Stock Exchange of India Limited (NSE) BSE Limited (BSE)		
10.	Issued Capital	No. of Shares	% of Total Issued Capital	
		13,34,27,000	100	



DMK ASSOCIATES COMPANY SECRETARIES

11.	Listed Capital (NSE & BSE)	13,33,94,400	99.98
	(as per company records)		
12.	Held in dematerialized Form in	107,38,226	8.05
	CDSL	, ,	5.05
13.	Held in dematerialized Form in	12,19,29,364	91.38
	NSDL		71.50
14.	Physical	7,59,410	0.57
		,,	0.57
15.	Total No. of Shares (12+13+14)	13,34,27,000	100
16.	Reasons for difference between		
10.	(10 &11)	22 600 Equity shares are held	l'
	(11 & 15)		in abeyance for which trading
	(11 & 13)	approval is not in place.	
	&		
	α		
	Passana fau 1:66		
	Reasons for difference between	N.A.	
	(10 & 15)		
17	C vici d d		7

17. Certifying the details of Changes in share capital during the quarter under consideration as per table below:

Particular	Shares	Applied/Not Applied for listing	Listed on Stock Exchanges (Specify Names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Appr. Pending for SE (Specify Names)
Allotmer of Equity Shares of Rs. 1/-eac on 20.07.202 on exercise of the options granted pursuant to Artemise Medicare Manageme Stock Option Pla — 2021	f hh 2 see	Applied	1) National Stock Exchange of India Limited 2) BSE Limited	YES	YES	
Allotmen of Equity Shares of Rs. 1/-each on 03.09.2022	1	Applied	1) National Stock Exchange of India Limited	YES	YES	



	on exercise	2) BSE			
	of the	Limited			
	options				
	granted				
	pursuant to				
	Artemis				
	Medicare				
	Management				
	Stock				
	G SERVI				
	Option Plan				
	<u>— 2021</u>				
	*Rights, bonus, Preferential Issue,	ESOPs, Amalgama	tion, Conversion	Buy Back	
	Capital Reduction Forfeiture, any	other (to specify)	,,	zuy zuck,	
		(- F - 5))			
18.	Register of Members is updated	Yes			
	(Yes/No) If not, updated upto				
	which date				
19.	Reference of previous quarter with	Nil	Mary 15		
	regard to excess dematerialized	1111			
	Shares, if any				
20.	Has the company resolved the	NA			
	matter mentioned in point No. 19	INA			
	above in the current quarter? If				
	not, reason why?				
21.					
	Mentioned the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:				
	Total no. of demat requests	No. of requests	No. of shares	Reasons for delay	
	Confirmed after 21 days	Nil	Nil ⁻	Nil	
-	Pending for more than 21 days	Nil	Nil	Nil	
				1,	
22.	Name, Telephone & Fax no. of the	Cl. D. II.			
	Compliance Officer of the	_			
	Company	Company Secretary & Compliance Officer			
	Company	91-124-4511-11	1		
		Resigned w.e.f	07.10.2022		
23.	Name, Address, Tel. & fax No.,	Deepak Kukrej	a		
	Reg. no. of Certifying Auditor	DMK Associate			
		Practicing Comp	oany Secretaries		
		31/36, Basement	t, Old Rajinder Na	gar	
		New Delhi-1100	060	P	
		C.P. No. 8265			
	ja .	Telefax: + 91-11	-42432721		
			12132721		
24.	Appointment of common agency	YES			
	for share Registry work.				
	If yes, (name & address)	Alankit Assignr	nents Limited		
		ALANKIT House	e Limiteu		
				1	



DMK ASSOCIATES COMPANY SECRETARIES

		4E/2, Jhandewalan Extension, New Delhi – 110055 Phone.: + 91-11-4254 1234 & 2354 1234 Fax: : + 91-11-23552001 Email info@alankit.com Website: www.alankit.com
25.	Any other detail that the auditor may like to provide	The Company has got permission from BSE & NSE for listing and trading of 300000 equity shares allotted on July 20, 2022 w.e.f July 29, 2022 and 300000 shares allotted on September 03, 2022 w.e.f. September 14, 2022 respectively.

FOR DMK ASSOCIATES COMPANY SECRETARIES

Place: New Delhi Date: 13.10.2022

UDIN: F004140D001218980



(DEEPAK KUKREJA) FCS, LLB., ACIS (UK), IP.

Partner
C.P. No. 8265
FCS No. 4140
Peer Review No. 779/2020